$-0.13
(Market cap
$1,131 Mln
Revenue (TTM)
$361 Mln
P/E Ratio
--
P/B Ratio
187.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
48.1
-
Debt to Equity
-5.4
-
Book Value
$--
-
EPS
$-0.1
-
Face value
--
-
Shares outstanding
308,950,166
10 Years Aggregate
CFO
$-458.84 Mln
EBITDA
$-663.16 Mln
Net Profit
$-978.34 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
MannKind Corp (MNKD)
| -31.7 | 25.2 | 39.7 | 4.3 | -2.6 | -1.1 | -2.8 |
|
BSE Sensex*
| -9.0 | 2.4 | 2.0 | -5.8 | 6.7 | 8.0 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
MannKind Corp (MNKD)
| -11.8 | 75.8 | -30.9 | 20.6 | 39.6 | 142.6 | 21.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
MannKind Corp (MNKD)
|
3.9 | 1,130.8 | 360.8 | -23.9 | 2.9 | -- | -- | 187.9 |
| 281.9 | 37,764.0 | 4,286.9 | 577.2 | 20.3 | 88.2 | 70.9 | 35.1 | |
| 231.2 | 14,299.5 | 867.5 | 506.6 | -0.6 | -- | 25 | 25.4 | |
| 52.1 | 13,354.5 | 2,375.5 | 833.4 | 41.5 | 40.7 | 17.6 | 6.9 | |
| 127.3 | 17,452.8 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 179.2 | 29,936.9 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.3 | 4.9 | |
| 461.6 | 13,347.1 | 2,678.3 | 460.4 | 21.3 | 103.2 | 29.4 | 22.3 | |
| 614.7 | 64,176.2 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 14.9 | 2.0 | |
| 548.3 | 23,174.2 | 3,169.8 | 1,287.4 | 51.3 | 20.6 | 20.2 | 3.9 | |
| 453.2 | 112,924.4 | 12,255.1 | 4,338.3 | 32.0 | 23.7 | 26.4 | 5.8 |
Shareholding Pattern
View DetailsAbout MannKind Corp (MNKD)
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary... hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. Read more
-
CEO & Director
Dr. Michael E. Castagna Pharm.D.
-
CEO & Director
Dr. Michael E. Castagna Pharm.D.
-
Headquarters
Danbury, CT
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for MannKind Corp (MNKD)
What is the current share price of MannKind Corp (MNKD) Today?
The share price of MannKind Corp (MNKD) is $3.87 (NASDAQ) as of 16-Jun-2026 16:21 EDT. MannKind Corp (MNKD) has given a return of -2.61% in the last 3 years.
What is the current PB & PE ratio of MannKind Corp (MNKD)?
Since, TTM earnings of MannKind Corp (MNKD) is negative, P/E ratio is not available.
The P/B ratio of MannKind Corp (MNKD) is 187.85 times as on 12-Jun-2026, a 4437 premium to its peers’ median range of 4.14 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
303.77
|
-34.91
|
|
2024
|
67.74
|
-23.71
|
|
2023
|
-98.75
|
-4.79
|
|
2022
|
-15.88
|
-5.54
|
|
2021
|
-13.56
|
-5.24
|
What is the 52 Week High and Low of MannKind Corp (MNKD)?
The 52-week high and low of MannKind Corp (MNKD) are Rs 6.51 and Rs 2.23 as of 17-Jun-2026.
What is the market cap of MannKind Corp (MNKD)?
MannKind Corp (MNKD) has a market capitalisation of $ 1,131 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in MannKind Corp (MNKD)?
Before investing in MannKind Corp (MNKD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.